top of page
Nelson Advisors > European HealthTech & MedTech Specialists


OpenEvidence: 'ChatGPT for Doctors' 2026 Plans and Strategic Outlook
OpenEvidence entered 2026 on an extraordinary growth arc. In January 2026, the Miami-based company closed a $250 Million Series D led by Thrive Capital and DST Global, doubling its valuation to $12 Billion, up from $6 Billion just three months earlier. The round brought total funding raised over the prior 12 months to nearly $700 Million, with backers including Sequoia Capital, Google Ventures (GV), Nvidia, Kleiner Perkins, Craft Ventures, Coatue, Blackstone, ICONIQ, Mayo Cl
14 hours ago7 min read
bottom of page